Higher serum potassium level associated with late stage chronic kidney disease

Chang Gung Medical Journal

Volumn 34, Issue 4, 2011, Pages 418-425

  Hsieh, Ming Fang ^a   Wu, I Wen ^a   Lee, Chin Chan ^a   Wang, Shun Yin ^a   Wu, Mai Szu ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Chronic kidney disease; Hyperkalemia

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; POTASSIUM;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG USE; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERKALEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; POTASSIUM;

EID: 80052652995     PISSN: 20720939     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. th ed. Philadelphia: Saunders, 2007:180-5.
2. Rastegar A, Soleimani M. Hypokalaemia and hyperkalaemia. Postgrad Med J 2001;77:759-64.
3. Ahmed J, Weisberg LS. Hyperkalemia in dialysis patients. Semin Dial 2001;14:348-56.
4. Giebisch G, Krapf R, Wagner C. Renal and extrarenal regulation of potassium. Kidney Int 2007;72:397-410.
5. Giebisch G. Renal potassium transport: mechanisms and regulation. Am J Physiol 1998;274:F817-33.
6. Giebisch G, Wang W. Potassium transport: From clearance to channels and pumps. Kidney Int 1996;49:1624-31.
7. Gennari FJ, Segal AS. Hyperkalemia: An adaptive response in chronic renal insufficiency. Kidney Int 2002;62:1-9.
8. Nielsen EH. Hyperkalaemic muscle paresis--side-effect of prostaglandin inhibition in a haemodialysis patient. Nephrol Dial Transplant 1999;14:480-2.
9. Wright FS. Sites and mechanisms of potassium transport along the renal tubule. Kidney Int 1977;11:415-32.
10. Levey A, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005;67:2089-100.
11. Tzamaloukas AH, Avasthi PS. Temporal profile of serum potassium concentration in nondiabetic and diabetic outpatients on chronic dialysis. Am J Nephrol 1987;7:101-9.
12. Aslam S, Friedman EA, Ifudu. Electrocardiography is unreliable in detecting potentially lethal hyperkalaemia in haemodialysis patients. Nephrol Dial Transplant 2002;17:1639-42.
13. Szerlip HM, Weiss J, Singer I. Profound hyperkalemia without electrocardiographic manifestations. Am J Kidney Dis 1986;7:461-5.
14. th ed, Philadelphia: Saunders, 2007;1265-79.
15. Schambelan M, Sebastian A, Biglieri EG. Prevalence, pathogenesis, and functional significance of aldosterone deficiency in hyperkalemic patients with chronic renal insufficiency. Kidney Int 1980;17:89-101.
16. Cannella G, Paoletti E, Delfino R, Peloso G, Rolla D, Molinari S. Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 1997;30:659-64.
17. Codreanu I, Perico N, Remuzzi G. Dual blockade of the renin-angiotensin system: the ultimate treatment for renal protection? J Am Soc Nephrol 2005;16 Suppl 1:S34-8.
18. Fioretto P, Solini A. Antihypertensive treatment and multifactorial approach for renal protection in diabetes. J Am Soc Nephrol 2005;16 Suppl 1:S18-21.
19. Bakris GL, Siomos M, Richardson D, Janssen I, Bolton WK, Hebert L, Agarwal R, Catanzaro D. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. Kidney Int 2000;58:2084-92.